Evidence map›Paper›PMID 19750229›Full record

ArticlePloS one2009

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.

Jose I Martin-Subero, Ole Ammerpohl, Marina Bibikova, Eliza Wickham-Garcia, Xabier Agirre, Sara Alvarez, Monika Brüggemann, Stefanie Bug, Maria J Calasanz, Martina Deckert and 25 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 137 citations in OpenAlex.

  1. Research progress on epigenetics of small B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The Emerging Roles of Heparan Sulfate 3-Frontiers in oncology · 2019
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 13 institutions in 4 countries.

Jose I Martin-SuberoInstitute of Human Genetics, Christian-Albrechts University, Kiel, Germany. jimartin@idibell.cat
Ole Ammerpohl
Marina Bibikova
Eliza Wickham-Garcia
Xabier Agirre
Sara Alvarez
Monika Brüggemann
Stefanie Bug
Maria J Calasanz
Martina Deckert
Martin Dreyling
Ming Q Du
Jan Dürig
Martin J S Dyer
Jian-Bing Fan
Stefan Gesk
Martin-Leo Hansmann
Lana Harder
Sylvia Hartmann
Wolfram Klapper
Ralf Küppers
Manuel Montesinos-Rongen
Inga Nagel
Christiane Pott
Julia Richter
José Román-Gómez
Marc Seifert
Harald Stein
Javier Suela
Lorenz Trümper
Inga Vater
Felipe Prosper
Claudia Haferlach
Juan Cruz Cigudosa
Reiner Siebert
Kiel University · DECentro Nacional de Epidemiología · ESIllumina (United States) · USUniversidad de Navarra · ESUniversity of Duisburg-Essen · DEUniversity Hospital Cologne · DEGoethe University Frankfurt · DEHospital Universitario Reina Sofía · ESMunich Leukemia Laboratory (Germany) · DEUniversity Hospital Frankfurt · DEUniversity of Cambridge · GBUniversity of Göttingen · DEUniversity of Leicester · GB

Funding

Medical Research Council MC_U132670597
6 · The paper itself

Abstract

backgroundAlterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities, and comprehensive studies are required. METHODOLOGY/PRINCIPAL

findingsHere, we report for the first time a microarray-based DNA methylation study of 767 genes in 367 HNs diagnosed with 16 of the most representative B-cell (n = 203), T-cell (n = 30), and myeloid (n = 134) neoplasias, as well as 37 samples from different cell types of the hematopoietic system. Using appropriate controls of B-, T-, or myeloid cellular origin, we identified a total of 220 genes hypermethylated in at least one HN entity. In general, promoter hypermethylation was more frequent in lymphoid malignancies than in myeloid malignancies, being germinal center mature B-cell lymphomas as well as B and T precursor lymphoid neoplasias those entities with highest frequency of gene-associated DNA hypermethylation. We also observed a significant correlation between the number of hypermethylated and hypomethylated genes in several mature B-cell neoplasias, but not in precursor B- and T-cell leukemias. Most of the genes becoming hypermethylated contained promoters with high CpG content, and a significant fraction of them are targets of the polycomb repressor complex. Interestingly, T-cell prolymphocytic leukemias show low levels of DNA hypermethylation and a comparatively large number of hypomethylated genes, many of them showing an increased gene expression. CONCLUSIONS/SIGNIFICANCE: We have characterized the DNA methylation profile of a wide range of different HNs entities. As well as identifying genes showing aberrant DNA methylation in certain HN subtypes, we also detected six genes--DBC1, DIO3, FZD9, HS3ST2, MOS, and MYOD1--that were significantly hypermethylated in B-cell, T-cell, and myeloid malignancies. These might therefore play an important role in the development of different HNs.

Indexed as

DNA MethylationB-LymphocytesCluster AnalysisCpG IslandsGene Expression ProfilingHematologic NeoplasmsHumansOligonucleotide Array Sequence AnalysisPromoter Regions, GeneticT-Lymphocytes

Identifiers

PMID19750229
PMCPMC2737286
OpenAlexW2145166916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.